Effects of CH 13.437 in different types of hyperlipidemia.
作者信息
Harvengt C
出版信息
Arch Int Pharmacodyn Ther. 1972 Apr;196:Suppl 196:298+.
PMID:4559547
Abstract
摘要
相似文献
1
Effects of CH 13.437 in different types of hyperlipidemia.
Arch Int Pharmacodyn Ther. 1972 Apr;196:Suppl 196:298+.
2
[Clinical evaluation of a new drug (CH 13437) in the treatment of hyperlipemia].
Rev Med Chil. 1970 Oct;98(10):689-94.
3
Comparative hypolipidaemic effectiveness of gum guggulu (Commiphora mukul) fraction 'A', ethyl-P-chlorophenoxyisobutyrate and Ciba-13437-Su.
Indian J Med Res. 1971 Oct;59(10):1621-32.
4
The hypolipidemic effect of SU-13,437 in rats with natural endogenous hypertriglyceridemia.
Lipids. 1971 Nov;6(11):783-6. doi: 10.1007/BF02531205.
5
[Therapeutic effect of Ciba 13437-Su in 40 patients with familial essential hyperlipemia].
Dtsch Med Wochenschr. 1970 Aug 28;95(35):1761-8. doi: 10.1055/s-0028-1108725.
6
[Treatment of essential hyperlipidemia with procetofene. Apropos of 100 cases].[用普罗赛芬治疗原发性高脂血症。附100例报告]
Sem Hop Ther. 1977 May-Jun;53(5-6):311-6.
7
Treatment of primary hyperlipoproteinaemias with a tetralin derivative (Su-13'437).用一种四氢化萘衍生物（Su-13'437）治疗原发性高脂蛋白血症。
Atherosclerosis. 1973 May-Jun;17(3):383-8. doi: 10.1016/0021-9150(73)90029-4.
8
Reduction of serum lipids in familial hyperlipidemias by a tetralin derivative.
Int Z Klin Pharmakol Ther Toxikol. 1969 Oct;2(4):348-53.
9
[Clinical trial of naproxen in the treatment of degenerative arthropathy (osteoarthritis)].
Scand J Rheumatol Suppl. 1973;2:72-6.
10
Growth and luteinizing hormone decreases during nafenoic acid therapy.萘酚酸治疗期间生长激素和促黄体生成素水平降低。
Pol Med Sci Hist Bull. 1971 Oct;14(4):148-53.
Zotero 插件